Related Experiment Videos
Size of cancer clinical trials and stopping rules
Abstract:
A recent international survey on the size of clinical trials in cancer showed the frequent problem of slow patient accrual, which remains a major hindrance to progress. The survey also revealed that, although the design of most trials specified a fixed number of patients, subsequent experience revealed a much more flexible approach, with analysis of results, say, every 4--6 months. Conventional sequential methods are hardly ever used and unfortunately most trials proceed without any predetermined stopping rules. Some trial organizers use repeated significance tests on accumulating data as a guide to the detection of treatment differences, an approach that can be adapted to a more rigorous statistical framework as a "group sequential design". The major statistical principle involved is that the more often one analyses the data the greater is the probability of achieving a statistically significant result, even when the two treatments are equally effective. Group sequential designs require the adoption of a more stringent significance level to allow for repeated testing. If one intends up to 10 repeated analyses of the data, only a treatment difference significant at the 1% level would merit a decision to stop the trial. For any trial to implement a stopping rule successfully there must also be prompt feedback and processing of response and survival data ready for up-to-date analysis. Such efficiency is often lacking. The repeated presentation of interim results of a trial to participating investigators can seriously affect their future reaction, especially if there are interesting but non-significant differences. Thus, some secrecy about ongoing results is advisable if trials are to achieve an unbiased conclusion.
Insights
Slow patient accrual in cancer clinical trials is a major hurdle. Group sequential designs offer a flexible approach with interim analyses, but require stringent statistical levels and efficient data processing to avoid bias.
Area of Science:
- Oncology
- Clinical Trial Design
- Biostatistics
Background:
- International survey highlights slow patient accrual as a significant barrier in cancer clinical trials.
- Most trials lack predetermined stopping rules, deviating from fixed-size designs towards flexible, interim analysis approaches.
Purpose of the Study:
- To explore the challenges in cancer clinical trial accrual and statistical analysis.
- To introduce group sequential designs as a rigorous statistical framework for interim data analysis in clinical trials.
Main Methods:
- Review of an international survey on clinical trial size and accrual.
- Discussion of statistical principles behind group sequential designs, including repeated significance testing and adjusted significance levels.
- Emphasis on the need for efficient data processing and feedback mechanisms.
Main Results:
- Slow patient accrual remains a frequent problem hindering cancer trial progress.
- Group sequential designs allow for repeated data analysis (e.g., every 4-6 months) but necessitate stricter significance levels (e.g., 1% for up to 10 analyses) to maintain trial integrity.
- Inefficient data processing and premature disclosure of interim results can bias trial outcomes.
Conclusions:
- Group sequential designs provide a structured approach to interim analyses in cancer trials.
- Successful implementation requires stringent statistical criteria, prompt data management, and careful consideration of result dissemination to maintain unbiased conclusions.